HPV16 and increased risk of recurrence after treatment for CIN

Murat Gök, Veerle M.H. Coupé, Johannes Berkhof, René H.M. Verheijen, Theo J.M. Helmerhorst, Cornelis J.A. Hogewoning, Peter J.F. Snijders, Chris J.L.M. Meijer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective.: Addition of high-risk human papillomavirus (hrHPV) testing to post-treatment monitoring policies of women treated for high-grade cervical intraepithelial neoplasia (CIN) may improve the effectiveness of detecting recurrent/residual disease. Recent studies have shown that HPV type 16 confers an increased risk of high-grade CIN and cervical cancer. This study aimed to find out whether the post-treatment CIN3 rate is increased in HPV16-positive women treated for CIN3. Methods.: We included 229 hrHPV-positive women treated for CIN3. HPV typing was performed by GP5+/6+-PCR followed by reverse line blotting on a cervical scrape taken before treatment. HPV typing data were related to the occurrence of post-treatment CIN3 within a median follow-up time of 20.1 months (range 3-85.4 months) following treatment. Results.: Twenty nine of the 151 (19%) HPV16-positive women versus 6 of the 78 (8%) women with other hrHPV types had recurrent/residual CIN3. Post-treatment CIN3 rate was significantly increased in women with HPV16 compared to those harboring other hrHPV types (p = 0.03). None of the other hrHPV types were associated with higher post-treatment CIN3 rates. Conclusion.: Women treated for HPV16 containing CIN3 should be monitored more intensively because of their increased risk of post-treatment CIN3. Thus, the HPV genotype should be considered in post-treatment monitoring policies.

Original languageEnglish
Pages (from-to)273-275
Number of pages3
JournalGynecologic Oncology
Issue number2
Publication statusPublished - 1 Feb 2007

Cite this